The import of insulin in dosage forms to Brazil stood at USD 44.35 million in 2023. According to forecasts, this value is expected to follow a steady upward trend from 2024 to 2028. Year-on-year variations indicate slight annual increases: 0.54% from 2024 to 2025, 0.52% from 2025 to 2026, 0.51% from 2026 to 2027, and 0.50% from 2027 to 2028. The compounded annual growth rate (CAGR) over this five-year period is approximately 0.52%.
Future trends to watch for include advancements in insulin delivery methods, potential market entry of biosimilar insulin products, and changes in healthcare policies that could impact import regulations or pricing structures. Additionally, monitoring the local production capabilities and economic conditions in Brazil will also be crucial for understanding any deviations from these forecasts.
